PAVmed (PAVM) Long-Term Investments (2024 - 2025)
PAVmed's (PAVM) quarterly Long-Term Investments came in at $34.1 million in Q4 2025, up 33.09% year-on-year from $25.6 million in Q4 2024, and up 7.92% quarter-over-quarter from $31.6 million in Q3 2025.
PAVmed (PAVM) Long-Term Investments (2024 - 2025) Analysis & Trends
PAVmed's Long-Term Investments history runs 2 years deep, the most recent figure standing at $34.1 million for Q4 2025.
- On a quarterly basis, Long-Term Investments rose 33.09% year-over-year to $34.1 million in Q4 2025; TTM through Dec 2025 was $34.1 million, a 33.09% increase from a year earlier, with the FY2025 full-year figure at $34.1 million, up 33.09% from the prior year.
- Long-Term Investments rose to $34.1 million in Q4 2025 per PAVM's latest filing, from $31.6 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $46.6 million in Q1 2025 and bottomed at $25.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.09 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 285.60 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 166.25 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 121.00 Mn |
| 10 | PAVmed | 9.85 Mn | -3.35 Mn | -4,000.00 | 34.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34.12 Mn |
| Sep 30, 2025 | 31.62 Mn |
| Jun 30, 2025 | 36.00 Mn |
| Mar 31, 2025 | 46.64 Mn |
| Dec 31, 2024 | 25.64 Mn |